This report studies the 23-Valent Pneumococcal Polysaccharide Vaccine market size (value and volume) by players, regions, product types and end industries, history data 2013-2017 and forecast data 2018-2025; This report also studies the global market competition landscape, market drivers and trends, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porter's Five Forces Analysis.
23-Valent Pneumococcal Polysaccharide Vaccine is a kind of vaccine used to prevent infection caused by pneumococcal bacteria. 23-Valent Pneumococcal Polysaccharide Vaccine contains 23 of the most common types of pneumococcal bacteria.
23-Valent Pneumococcal Polysaccharide Vaccine is for use only in adults and children who are at least 2 years old. For children younger than 2 years old, another vaccine called Prevnar (pneumococcal conjugate vaccine [PCV] 7-valent) is used, usually given between the ages of 2 months and 15 months.
North America is the largest supplier and consumption market of 23-Valent Pneumococcal Polysaccharide Vaccine, with a production market share nearly 70% and sales market share nearly 28% in 2015. Because Sanofipasteur, a competitor from Europe, transferred its vaccine type gradually, the production market share of North America in the world has enjoyed a dramatic increase.
The second place is EU, following North America with production market share of 15% and sales market share nearly 20% in 2015.China is another important market of 23-Valent Pneumococcal Polysaccharide Vaccine, enjoying 10% production market share and 15% sales market share in 2015.
The global 23-Valent Pneumococcal Polysaccharide Vaccine market was 1550 million US$ in 2017 and is expected to 4550 million US$ by the end of 2025, growing at a CAGR of 14.4% between 2018 and 2025.
Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth Rate of 23-Valent Pneumococcal Polysaccharide Vaccine in these regions, from 2013 to 2025, covering
North America (United States, Canada and Mexico)
Europe (Germany, UK, France, Italy, Russia and Turkey etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
South America (Brazil etc.)
Middle East and Africa (Egypt and GCC Countries)
The various contributors involved in the value chain of the product include manufacturers, suppliers, distributors, intermediaries, and customers. The key manufacturers in this market include
By the product type, the market is primarily split into
Single Dose Vial
By the end users/application, this report covers the following segments
For Children (2-10)
For Person (10-64)
For The Old (≥65)
We can also provide the customized separate regional or country-level reports, for the following regions:
Rest of Asia-Pacific
Rest of Europe
Central & South America
Rest of Central & South America
Middle East & Africa
Rest of Middle East & Africa
The study objectives of this report are:
To study and analyze the global 23-Valent Pneumococcal Polysaccharide Vaccine market size (value & volume) by company, key regions/countries, products and application, history data from 2013 to 2017, and forecast to 2025.
To understand the structure of 23-Valent Pneumococcal Polysaccharide Vaccine market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global 23-Valent Pneumococcal Polysaccharide Vaccine manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the 23-Valent Pneumococcal Polysaccharide Vaccine with respect to individual growth trends, future prospects, and their contribution to the total market.
To project the value and volume of 23-Valent Pneumococcal Polysaccharide Vaccine submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
In this study, the years considered to estimate the market size of 23-Valent Pneumococcal Polysaccharide Vaccine are as follows:
History Year: 2013-2017
Base Year: 2017
Estimated Year: 2018
Forecast Year 2018 to 2025
This report includes the estimation of market size for value (million USD) and volume (K Dose). Both top-down and bottom-up approaches have been used to estimate and validate the market size of 23-Valent Pneumococcal Polysaccharide Vaccine market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2017 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Raw material suppliers
Regulatory bodies, including government agencies and NGO
Commercial research & development (R&D) institutions
Importers and exporters
Government organizations, research organizations, and consulting firms
Trade associations and industry bodies
With the given market data, QYResearch offers customizations according to the company's specific needs. The following customization options are available for the report:
Further breakdown of 23-Valent Pneumococcal Polysaccharide Vaccine market on basis of the key contributing countries.
Detailed analysis and profiling of additional market players.